GODZILLA - (60mg,30mg, 20mg, 10mg, 5mg)

GODZILLA - (60mg,30mg, 20mg, 10mg, 5mg)

5
R 998.00
R 998.00
Skip to product information
GODZILLA - (60mg,30mg, 20mg, 10mg, 5mg)
  • GODZILLA - (60mg,30mg, 20mg, 10mg, 5mg)
  • GODZILLA - (60mg,30mg, 20mg, 10mg, 5mg)
GODZILLA - (60mg,30mg, 20mg, 10mg, 5mg)

GODZILLA - (60mg,30mg, 20mg, 10mg, 5mg)

R 998.00
R 998.00
mg

PRODUCT DESCRIPTION

Peptide Name: LY3437943

 

RESEARCHED AREAS AND BENEFITS

  • Triple receptor agonism synergy

  • Unprecedented weight reduction efficacy

  • Hepatic steatosis resolution focus

  • Glycemic control insulin sensitivity

  • Energy expenditure metabolic increase

 

Chemical Name: L-Serinamide, L-tyrosyl-2-methylalanyl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-2-methyl-L-leucyl-L-leucyl-L-alpha-aspartyl-L-lysyl-N6-[N-(19-carboxy-1-oxononadecyl)-L-gamma-glutamyl-2-[2-(2-aminoethoxy)ethoxy]acetyl]-L-lysyl-L-alanyl-L-glutaminyl-2-methylalanyl

CAS Number: 2381089-83-2

 

DESCRIPTION

RT is an investigational, first-in-class "triple G" agonist that targets three essential nutrient-stimulated hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG). By integrating these three pathways into a single peptide backbone, RT aims to achieve metabolic outcomes that exceed those of dual-agonist therapies like TZ. The addition of glucagon receptor activity is particularly significant, as it is researched for its ability to increase energy expenditure and fat oxidation directly in the liver, while the GLP-1 and GIP components manage appetite and glucose-dependent insulin secretion.

 

  • Weight Management: Phase 3 clinical trials (2025-2026) have shown mean weight reductions exceeding 24% over 48 weeks, approaching the efficacy typically seen with bariatric surgery.

  • Metabolic Health: Studies demonstrate significant improvements in HbA1c levels, with many participants achieving normoglycemia (A1C < 5.7%) during the trial period.

  • Liver Fat Reduction: Research indicates a potent effect on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), with up to 90% of subjects in subset studies achieving normalization of liver fat.

  • Cardiovascular Markers: Data suggests secondary benefits in reducing systolic blood pressure and improving lipid profiles, specifically triglycerides and non-HDL cholesterol.

 

KIT INCLUDES:

1x Peptide Vial

1x 10ml BAC Water

1x Reconstitution Kit

 

REGULATORY NOTICES

SAHPRA DISCLAIMER This product has not been evaluated by the South African Health Products Regulatory Authority (SAHPRA). It is not intended to diagnose, treat, cure, or prevent any disease.

RESEARCH USE ONLY 

 

SCIENTIFIC STUDIES

  • Triple-Hormone-Receptor Agonist RT for Obesity: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

  • RT (LY3437943), a novel GIP, GLP-1, and glucagon receptor agonist: https://pmc.ncbi.nlm.nih.gov/articles/PMC11486854/

  • Lilly's Triple Agonist RT Phase 3 Diabetes Results (March 2026): https://investor.lilly.com/news-releases/

  • Efficacy and safety of rT in obesity treatment - A Systematic Review: https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/

You may also like